New Study of Seraph Affinity Apheresis Device Demonstrates Potential for Reducing the High Death Rate from Sepsis, a Top-10 Cause of Death in the U.S.

June 13, 2011
ExThera Medical Corporation announced Monday that a new study of its breakthrough Seraph (Selective Removal by Apheresis) affinity therapy device demonstrates its potential as a treatment for patients suffering from Staphylococcus aureus- and/or Methicillin-Resistant S. aureus (MRSA)-induced sepsis.